LUCID DIAGNOSTICS INC (LUCD)

Company Profile

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. The company is also developing EsoCure, which is an esophageal ablation device to treat dysplastic BE before it can progress to EAC.

Company Info

LUCID DIAGNOSTICS INC

360 Madison Avenue, 25th Floor

New York City NEW YORK

P: 12129494319

Employees: 74

Website: https://www.luciddx.com/